Avtor/Urednik		Jensterle Sever, Mojca; Goričar, Katja; Janež, Andrej
Naslov		Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved [beta]-cell function and insulin sensitivity in metformin treated PCOS
Tip		članek
Leto izdaje		2017
Obseg		str. str.
ISSN		0743-5800 - Endocrine research
Jezik		eng
Abstrakt		Purpose: Impaired [beta]-cell function remains unaddressed in PCOS. The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves [beta]-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR. Materials and methods: In 12-week randomized study, ALO 25 mg QD (n=15) or ALO 25 mg QD and PIO 30 mg QD (n=15) was added to MET 1000 mg BID in PCOS women (aged 34.4 - 6.5 years, BMI 39.0 +- 4.9 kg/m2, HOMA-IR 4.82 +- 2.52, mean +- SD). Model derived parameters of glucose homeostasis from the meal tolerance test (MTT) were determined. The ability of the [beta]-cell function was assessed by the adaptation index (AI). Results: MET-ALO and MET-ALO-PIO resulted in a significant decrease of HOMA-IR (by 1.6+-2.3 (p=0.039) and 2.9-3.3 (p=0.001), respectively) and an increase in insulin sensitivity (IS) after meal ingestion (oral glucose IS) by 31.4+-97.5 ml.min-1.m-2 (p=0.007) vs 39.0-58.1 ml.min-1.m-2 (p=0.039), respectively. AI across the entire group was significantly improved from 329.6+-200.6 to 442.5+-303.9 (p=0.048). Conclusions: ALO alone and in combination with PIO improved IR along with dynamic IS and meal related [beta]-cell function when added to MET treated PCOS.
Proste vsebinske oznake		alogliptin PCOS obesity beta-cell function alogliptin PCOS debelost funkcija beta celic